1-7 of 7
Xin Zhang
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Molecular Characteristics of Repotrectinib That Enable Potent Inhibition of TRK Fusion Proteins and Resistant Mutations

Brion W. Murray, Evan Rogers, Dayong Zhai, Wei Deng, Xi Chen, Paul A. Sprengeler, Xin Zhang, Armin Graber, Siegfried H. Reich, Shanna Stopatschinskaja, Benjamin Solomon, Benjamin Besse, Alexander Drilon
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2021) 20 (12): 2446–2456.
https://doi.org/10.1158/1535-7163.MCT-21-0632
Published: 01 December 2021
View article titled, Molecular Characteristics of Repotrectinib That Enable Potent Inhibition of TRK Fusion Proteins and Resistant Mutations
Open the PDF for Molecular Characteristics of Repotrectinib That Enable Potent Inhibition of TRK Fusion Proteins and Resistant Mutations in another window
Journal Articles

TPX-0131, a Potent CNS-penetrant, Next-generation Inhibitor of Wild-type ALK and ALK-resistant Mutations

Brion W. Murray, Dayong Zhai, Wei Deng, Xin Zhang, Jane Ung, Vivian Nguyen, Han Zhang, Maria Barrera, Ana Parra, Jessica Cowell, Dong J. Lee, Herve Aloysius, Evan Rogers
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2021) 20 (9): 1499–1507.
https://doi.org/10.1158/1535-7163.MCT-21-0221
Published: 01 September 2021
View article titled, TPX-0131, a Potent CNS-penetrant, Next-generation Inhibitor of Wild-type ALK and ALK-resistant Mutations
Open the PDF for TPX-0131, a Potent CNS-penetrant, Next-generation Inhibitor of Wild-type ALK and ALK-resistant Mutations in another window
Journal Articles

Correction: MALAT1 is Associated with Poor Response to Oxaliplatin-based Chemotherapy in Colorectal Cancer Patients and Promotes Chemoresistance through EZH2

Peilong Li, Xin Zhang, Haiyan Wang, Lili Wang, Tong Liu, Lutao Du, Yongmei Yang, Chuanxin Wang
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2021) 20 (2): 451.
https://doi.org/10.1158/1535-7163.MCT-20-1028
Published: 05 February 2021
View article titled, Correction: MALAT1 is Associated with Poor Response to Oxaliplatin-based Chemotherapy in Colorectal Cancer Patients and Promotes Chemoresistance through EZH2
Open the PDF for Correction: MALAT1 is Associated with Poor Response to Oxaliplatin-based Chemotherapy in Colorectal Cancer Patients and Promotes Chemoresistance through EZH2 in another window
Journal Articles

Genotyping of Circulating Tumor DNA Reveals the Clinically Actionable Mutation Landscape of Advanced Colorectal Cancer

Weiguo Cao, Yaping Xu, Lianpeng Chang, Yuhua Gong, Liren Li, Xianwei Mo, Xin Zhang, Guole Lin, Jiaolin Zhou, Dan Liu, Yuting Yi, Pingping Dai, Chenchen Zhu, Tao Liu, Yuxing Chu, Yanfang Guan, Yongsheng Chen, Jiayin Wang, Xuefeng Xia, Ling Yang, Xin Yi, Yong Cheng
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (6): 1158–1167.
https://doi.org/10.1158/1535-7163.MCT-18-1247
Published: 03 June 2019
View article titled, Genotyping of Circulating Tumor DNA Reveals the Clinically Actionable Mutation Landscape of Advanced Colorectal Cancer
Open the PDF for Genotyping of Circulating Tumor DNA Reveals the Clinically Actionable Mutation Landscape of Advanced Colorectal Cancer in another window
Includes: Supplementary data
Journal Articles

MALAT1 Is Associated with Poor Response to Oxaliplatin-Based Chemotherapy in Colorectal Cancer Patients and Promotes Chemoresistance through EZH2

Peilong Li, Xin Zhang, Haiyan Wang, Lili Wang, Tong Liu, Lutao Du, Yongmei Yang, Chuanxin Wang
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2017) 16 (4): 739–751.
https://doi.org/10.1158/1535-7163.MCT-16-0591
Published: 02 April 2017
View article titled, MALAT1 Is Associated with Poor Response to Oxaliplatin-Based Chemotherapy in Colorectal Cancer Patients and Promotes Chemoresistance through EZH2
Open the PDF for MALAT1 Is Associated with Poor Response to Oxaliplatin-Based Chemotherapy in Colorectal Cancer Patients and Promotes Chemoresistance through EZH2 in another window
Includes: Supplementary data
Journal Articles

DLK1 as a Potential Target against Cancer Stem/Progenitor Cells of Hepatocellular Carcinoma

Xiao Xu, Rui-Fang Liu, Xin Zhang, Li-Yu Huang, Fei Chen, Qian-Lan Fei, Ze-Guang Han
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2012) 11 (3): 629–638.
https://doi.org/10.1158/1535-7163.MCT-11-0531
Published: 06 March 2012
View article titled, DLK1 as a Potential Target against Cancer Stem/Progenitor Cells of Hepatocellular Carcinoma
Open the PDF for DLK1 as a Potential Target against Cancer Stem/Progenitor Cells of Hepatocellular Carcinoma in another window
Includes: Supplementary data
Journal Articles

Interaction between epidermal growth factor receptor– and cyclooxygenase 2–mediated pathways and its implications for the chemoprevention of head and neck cancer

Mi Sun Choe, Xin Zhang, Hyung Ju C. Shin, Dong M. Shin, Zhuo (Georgia) Chen
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2005) 4 (9): 1448–1455.
https://doi.org/10.1158/1535-7163.MCT-04-0251
Published: 16 September 2005
View article titled, Interaction between epidermal growth factor receptor– and cyclooxygenase 2–mediated pathways and its implications for the chemoprevention of head and neck cancer
Open the PDF for Interaction between epidermal growth factor receptor– and cyclooxygenase 2–mediated pathways and its implications for the chemoprevention of head and neck cancer in another window